Cellular Origins and Cell and Gene Therapy Catapult collaborate to demonstrate universal automation of CGT manufacturing

FHS
May 29, 2024
10:49 am

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specializing in the advancement of the cell and gene therapy industry, today announced a collaboration to demonstrate universal automation of CGT manufacturing.

Roche to acquire Poseida Therapeutics for $1.5bn

The partnership between Roche and Poseida began in 2022, focusing on the development of off-the-shelf CAR-T cell therapies. Credit: metamorworks/Shutterstock. Roche has signed an agreement

November 26, 2024

As government shutdown looms, medical device reviews expected to continue

Dive Brief: In the event of a government shutdown, the Food and Drug Administration would be able to continue with product reviews thanks to funding

September 28, 2023

How indoor microbiomes shape our health and well-being

Indoor microbiomes, influenced by urbanization and building design, significantly impact human immune, neurological, and endocrine health. This research emphasizes the need for innovative approaches to

July 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.